Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Circadian Rhythms and Gene Regulation02:19

Circadian Rhythms and Gene Regulation

The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent years,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

High-Speed Atomic Force Microscopy Reveals Aptamer-Mediated Conformational Trapping of METTL3-METTL14 for m<sup>6</sup>A Inhibition.

ACS applied materials & interfaces·2026
Same author

An in vitro approach to predict idiosyncratic drug-induced agranulocytosis using myeloperoxidase-derived reactive metabolites.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Identification of alcohol dehydrogenase (ADH) isoforms catalyzing hydroxyzine oxidation using recombinant human ADH: Serendipitous finding of potent ADH inhibition by organic solvents.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Arylacetamide deacetylase attenuates hepatic lipid accumulation under ER stress conditions by regulating iron-dependent oxidative stress.

Toxicology and applied pharmacology·2026
Same author

Arylacetamide deacetylase deficiency potentiates ketoconazole-induced inhibition of triazolam metabolism in mice.

Drug metabolism and pharmacokinetics·2026

Related Experiment Video

Updated: Jun 18, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Human CYP2E1 is regulated by miR-378.

Takuya Mohri1, Miki Nakajima, Tatsuki Fukami

  • 1Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

Biochemical Pharmacology
|December 1, 2009
PubMed
Summary

MicroRNA-378 (miR-378) regulates human CYP2E1 expression by inhibiting translation, not mRNA stability. This finding clarifies post-transcriptional regulation mechanisms for this important enzyme.

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Human CYP2E1 is a critical enzyme in drug metabolism and toxicology.
  • Previous research indicated post-transcriptional and post-translational regulation of CYP2E1, but the precise mechanisms were unknown.

Purpose of the Study:

  • To investigate the role of microRNA in the post-transcriptional regulation of human CYP2E1.
  • To identify specific microRNAs that may target CYP2E1 mRNA.

Main Methods:

  • In silico analysis to predict microRNA binding sites in the CYP2E1 3'-UTR.
  • Luciferase reporter assays to confirm miR-378 binding to the predicted site.
  • Stable cell line experiments to assess the impact of miR-378 on CYP2E1 protein and activity.
  • Analysis of human liver samples to correlate miR-378 and CYP2E1 levels.

Main Results:

  • miR-378 was identified as a potential regulator of human CYP2E1 via its 3'-UTR.
  • Luciferase assays confirmed functional recognition of the miR-378 binding site.
  • Overexpression of miR-378 reduced CYP2E1 protein levels and enzyme activity, but not mRNA levels or stability.
  • Inverse correlation observed between miR-378 and CYP2E1 protein levels in human livers.

Conclusions:

  • Human CYP2E1 expression is regulated by miR-378, primarily through translational repression.
  • This study elucidates a novel post-transcriptional regulatory mechanism for CYP2E1.
  • Findings contribute to understanding the complex regulation of cytochrome P450 enzymes.